Resources

Synecta T1 Enables Accelerated, Potent T Cell Expansion For Scalable Adoptive Immunotherapy Manufacturing

Cytiva’s Fast Trak™ (services for process development and training) evaluated Synecta T1 across both small- and large-scale expansion systems to benchmark performance against a conventional activation reagent to assess fold expansion, viability, and scalability in T-cell manufacturing workflows.

Improved T-cell Expansion, Viability, and Metabolic Fitness with Synecta Cell-Derived Nanoparticles Across Clinically-Relevant Media Conditions

Evaluation of huCART19-IL18 Manufactured Using Synecta CDNP Technology to Improve CAR-T Yield and Consistency in Cohort D of an Ongoing Phase I Study (NCT04684563)

Cell-Derived Nanoparticle Platform Offers Versatile Use of Membrane-Bound and Soluble Cytokines for Rapid and Efficient CAR-T Cell Production

Break The Cell Therapy Manufacturing Bottleneck With Day-0 Transduction, Day-3 Harvest